Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 2
2014 pubmed 32 citations

Acute and chronic effects of kisspeptin-54 administration on GH, prolactin and TSH secretion in healthy women.

Jayasena. Channa N CN; Comninos. Alexander N AN; Narayanaswamy. Shakunthala S; Bhalla. Sanjana S; Abbara. Ali A; Ganiyu-Dada. Zainab Z; Busbridge. Mark M; Ghatei. Mohammad A MA; Bloom. Stephen R SR; Dhillo. Waljit S WS

Key Findings

  • Kisspeptin‑54 did not acutely alter GH, prolactin, or TSH within 4 hours of injection.
  • Twice‑daily kisspeptin‑54 for 7 days did not produce chronic changes in GH, prolactin, or TSH.
  • The dose used was enough to stimulate gonadotropins but showed no significant off‑target hormone effects.

Practical Outcomes

  • For biohackers interested in using kisspeptin‑10 or related compounds for fertility or metabolic benefits, this study suggests the standard dose is unlikely to cause unwanted spikes in growth, prolactin, or thyroid hormones. However, the sample size is tiny, so monitor personal hormone responses if experimenting.

Summary

In a small study of five healthy women, giving kisspeptin‑54 twice daily for a week didn’t change growth hormone, prolactin, or thyroid‑stimulating hormone levels either right after a dose or over the whole week, even though the same dose does boost fertility hormones. This suggests kisspeptin‑54 is unlikely to mess with those other pituitary hormones at the studied dose.

Abstract

The peptide hormone kisspeptin is essential for human reproduction, acting on the hypothalamus to stimulate gonadotrophin-releasing hormone (GnRH) secretion. Kisspeptin is currently being evaluated as a novel therapeutic for women with infertility. However, some animal studies suggest that kisspeptin may also stimulate growth hormone (GH), prolactin and thyroid-stimulating hormone (TSH) secretion, with implications for its safety; no previous study has investigated whether kisspeptin stimulates these pituitary hormones in humans. To determine whether kisspeptin-54 modulates GH, prolactin and TSH secretion in healthy women. Prospective, single-blinded, placebo-controlled, one-way crossover study. Five healthy women received 7 days of twice-daily subcutaneous bolus vehicle (month 1) or 6·4 nmol/kg kisspeptin-54 (month 2). Serum samples were analysed post hoc for GH, prolactin and TSH. Mean serum GH, PRL and TSH did not change during the first 4 h following kisspeptin-54 injection when compared with vehicle. The mean frequency or amplitude of GH pulses (which influence GH function) did not change acutely following kisspeptin-54 injection when compared with vehicle. No chronic changes in serum GH, PRL or TSH were observed over the 7-day period of twice-daily kisspeptin-54 injections when compared with vehicle. While we cannot exclude any effect of kisspeptin-54 on GH, prolactin or TSH secretion, we observed no significant changes in these hormones at a dose of kisspeptin-54 administration known to stimulate gonadotrophin secretion in a small study of healthy women. These data have important implications for the potential of kisspeptin to treat patients with infertility.

Study Information

Provider

pubmed

Year

2014

Date

2014-06-25T00:00:00.000Z

DOI

10.1111/cen.12512

Citations

32

References

37